Compare
Verastem, Inc. vs Foghorn Therapeutics Inc. vs Zomedica Corp. vs Cue Biopharma, Inc.
| Latest fiscal year | Verastem, Inc. VSTM | Foghorn Therapeutics Inc. FHTX | Zomedica Corp. ZOMDF | Cue Biopharma, Inc. CUE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $30.91M | $30.91M | $32.03M | $27.47M |
| Revenue growth (YoY) | +209.1% | +36.8% | +17.4% | +195.7% |
| Gross margin | n/a | n/a | 67.7% | n/a |
| Operating margin | -550.3% | -279.5% | -263.4% | -96.7% |
| Net margin | -677.6% | -240.3% | -255.6% | -96.9% |
| Net income | -$209.47M | -$74.28M | -$81.86M | -$26.60M |
| EPS (Diluted) | -$3.02 | -$1.18 | -$0.08 | -$0.28 |
| Operating cash flow | -$137.51M | -$86.10M | -$17.65M | -$21.69M |
| Free cash flow | n/a | -$86.15M | -$18.22M | -$21.86M |
| Cash & equivalents | $204.99M | $80.88M | $9.02M | $27.14M |
| Total assets | $246.44M | $198.10M | $127.04M | $42.21M |
| Total liabilities | $189.25M | $306.60M | $11.64M | $15.78M |
| Shareholders' equity | $57.20M | -$108.50M | $115.40M | $26.43M |
| Return on year-end equity | -366.2% | n/a | -70.9% | -100.6% |
| Shares outstanding | 77.74M | 56.66M | 979.95M | 96.62M |
Revenue, most recent five fiscal years
| Fiscal year | Verastem, Inc. | Foghorn Therapeutics Inc. | Zomedica Corp. | Cue Biopharma, Inc. |
|---|---|---|---|---|
| Latest | $30.91M Ended 2025-12-31 | $30.91M Ended 2025-12-31 | $32.03M Ended 2025-12-31 | $27.47M Ended 2025-12-31 |
| 1 year earlier | $10.00M Ended 2024-12-31 | $22.60M Ended 2024-12-31 | $27.29M Ended 2024-12-31 | $9.29M Ended 2024-12-31 |
| 2 years earlier | n/a | $34.16M Ended 2023-12-31 | $25.19M Ended 2023-12-31 | $5.49M Ended 2023-12-31 |
| 3 years earlier | $2.60M Ended 2022-12-31 | $19.23M Ended 2022-12-31 | $18.93M Ended 2022-12-31 | $1.25M Ended 2022-12-31 |
| 4 years earlier | $2.05M Ended 2021-12-31 | $1.32M Ended 2021-12-31 | $4.13M Ended 2021-12-31 | $14.94M Ended 2021-12-31 |